CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19

NCT04356482 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2020-06-05

No results posted yet for this study

Summary

The present study will try to respond first in an initial phase, what is the minimum effective dose necessary of convalescent plasma for getting better in severly ill (not intubated) or very severely ill (intubated) patients.

Once the dose will be determined by each type of patient group (severely ill vs. very severely ill) has been determined, phase 2 of the study will begin, where the safety and efficacy of the use of plasma will be evaluated based on clinical, imaging and laboratory criteria.

So, our hypotheses are:

1. Is there a minimum effective dose to treat seriously ill patients with convalescent plasma with COVID-19?
2. the plasma dose with the minimum effective effect will improve the clinical, laboratory and clearance conditions of the presence of the virus in the severely ill patient?

Conditions

  • COVID-19
  • SARS-CoV 2
  • Convalescence
  • Plasma
  • Doses

Interventions

BIOLOGICAL

convalescent plasma

In phase 1, different amounts of convalescent plasma will be evaluated depending on the severity of the case. In phase 2, both clinical, laboratory, imaging and viral presence (effectiveness) and safety will be evaluated.

Sponsors & Collaborators

  • SECRETARIA DE SALUD DEL ESTADO DE SONORA

    collaborator UNKNOWN
  • CENTRO ESTATAL DE LA TRANSFUSION SANGUINEA

    collaborator UNKNOWN
  • HOSPITAL CENTRAL NACIONAL PEMEX NORTE

    collaborator UNKNOWN
  • HOSPITAL DE ZONA No. 2 IMSS

    collaborator UNKNOWN
  • HOSPITAL DE ZONA No.14 IMSS

    collaborator UNKNOWN
  • HOSPITAL GENERAL DEL ESTADO DE SONORA

    collaborator UNKNOWN
  • Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

    lead OTHER_GOV

Principal Investigators

  • Luis M Villela, MD · ISSSTESON

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-20
Primary Completion
2020-11-30
Completion
2020-12-31

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04356482 on ClinicalTrials.gov